AbbVie Inc. (ABBV34.SA)
São Paulo - São Paulo Delayed price. Currency in BRL
Add to watchlist
At close: 05:05PM BRT
| Previous close | 56.10 |
| Open | 0.00 |
| Bid | 55.50 x 0 |
| Ask | 57.25 x 0 |
| Day's range | 0.00 - 0.00 |
| 52-week range | |
| Volume | |
| Avg. volume | 4,268 |
| Market cap | 1.597T |
| Beta (5Y monthly) | 0.58 |
| PE ratio (TTM) | 49.96 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 1.46 (2.59%) |
| Ex-dividend date | 12 Apr 2024 |
| 1y target est | N/A |
- Zacks
Pharma Stock Roundup: FDA Panel Endorses LLY's Donanemab, PFE's DMD Therapy Study Fails
An FDA panel endorses Eli Lilly's (LLY) Alzheimer's disease drug, donanemab. Pfizer's (PFE) DMD study on investigational gene therapy fails.
- Zacks
AbbVie (ABBV) Buys Global Rights to Novel IBD Candidate
AbbVie (ABBV) signs an exclusive global licensing deal with the Chinese company FutureGen to develop FG-M701, a next-generation TL1A antibody, for IBD indications.
- Zacks
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
© 2024 Yahoo. All rights reserved.